20n Bio

20n Bio is an early-stage biotechnology company based in Malvern, Pennsylvania, that utilizes artificial intelligence and computational biology to design and screen cyclic peptides for novel therapeutics. The venture-backed biopharmaceutical startup focuses on discovering peptide drugs for challenging biological targets, particularly within oncology and other high-value disease areas that are difficult to address with traditional small molecules or large biologics. Operating with a dedicated team of one to ten employees, the enterprise emerged from stealth mode in late 2021 after successfully securing a total of $3.3 million in seed funding. This initial investment round was led by BRV China, providing essential capital to validate its proprietary binder design platform and advance multiple discovery programs under the strategic leadership of President Linghang Zhuang. 20n Bio was officially founded in 2021 by chief executive officer Mingfu Zhu.